Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

New frontiers in chronic lymphocytic leukemia on the way to curing the disease editorial memo (2022) 15:3 https://doi.org/10.1007/s12254-022-00795-9 New frontiers in chronic lymphocytic leukemia on the way to curing the disease Philipp Staber Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 References Chronic lymphocytic leukemia (CLL) is the most com- mon leukemia in the western world and is consid- ered to be incurable. In the last 10 years, novel ther- Cited Literature apeutics, like B cell receptor blockers and the bcl-2 1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, inhibitor venetoclax have transformed the prognosis Dighiero G, Döhner H, et al. iwCLL guidelines for diag- for CLL patients [1]. In this issue of the Magazine of nosis, indications for treatment, response assessment, and European Medical Oncology (MEMO),we discuss the supportive management of CLL. Blood. 2018;131:2745–60. perspectives of novel strategies to actually cure CLL 2. Heintel D. BTKi, venetoclax, obinutuzumab: what is the patients. ideal combination?. memo. 2021. https://doi.org/10.1007/ Daniel Heintel reviews the current treatment op- s12254-021-00776-4. 3. Prochazka KT, Uhl B. Bcl2 inhibitor venetoclax +/– Anti- tions for patients with CLL with respect to potential CD20: what do deep remissions mean?. memo. 2021. optimal treatment combinations [2]. Katharina Proc- https://doi.org/10.1007/s12254-021-00778-2. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

Download PDF
1 page

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

Abstract

editorial memo (2022) 15:3 https://doi.org/10.1007/s12254-022-00795-9 New frontiers in chronic lymphocytic leukemia on the way to curing the disease Philipp Staber Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 References Chronic lymphocytic leukemia (CLL) is the most com- mon leukemia in the western world and is consid- ered to be incurable. In the last 10 years, novel ther- Cited Literature apeutics, like...
Loading next page...
 
/lp/springer-journals/new-frontiers-in-chronic-lymphocytic-leukemia-on-the-way-to-curing-the-UzlXnewCEs
Publisher
Springer Journals
Copyright
2022 The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-022-00795-9
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2022) 15:3 https://doi.org/10.1007/s12254-022-00795-9 New frontiers in chronic lymphocytic leukemia on the way to curing the disease Philipp Staber Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 References Chronic lymphocytic leukemia (CLL) is the most com- mon leukemia in the western world and is consid- ered to be incurable. In the last 10 years, novel ther- Cited Literature apeutics, like B cell receptor blockers and the bcl-2 1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, inhibitor venetoclax have transformed the prognosis Dighiero G, Döhner H, et al. iwCLL guidelines for diag- for CLL patients [1]. In this issue of the Magazine of nosis, indications for treatment, response assessment, and European Medical Oncology (MEMO),we discuss the supportive management of CLL. Blood. 2018;131:2745–60. perspectives of novel strategies to actually cure CLL 2. Heintel D. BTKi, venetoclax, obinutuzumab: what is the patients. ideal combination?. memo. 2021. https://doi.org/10.1007/ Daniel Heintel reviews the current treatment op- s12254-021-00776-4. 3. Prochazka KT, Uhl B. Bcl2 inhibitor venetoclax +/– Anti- tions for patients with CLL with respect to potential CD20: what do deep remissions mean?. memo. 2021. optimal treatment combinations [2]. Katharina Proc- https://doi.org/10.1007/s12254-021-00778-2.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Feb 1, 2022

Keywords: oncology; medicine/public health, general

There are no references for this article.